MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$3,116K
Free Cash flow
-$25,577K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from sales and maturiti...
    • Stock-based compensation expense
    • Other
    • Depreciation expense
Negative Cash Flow Breakdown
    • Net loss
    • Purchases of investments
    • Prepaid expenses and other curre...
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-22,969 -20,555 -23,342 -34,640
Stock-based compensation expense
1,916 1,429 1,582 3,277
Depreciation expense
49 49 50 134
Net amortization of premiums and discounts on investments
346 692 50 624
Amortization of debt discount
-0 0 0
Other
-84 -13 -47 289
Prepaid expenses and other current assets
1,947 -297 -2,656 2,319
Decrease in other assets
-0 0 0
Decrease in operating lease liabilities
--416 -407 -783
Decrease in operating lease right-of-use asset
--275 -267 -509
Decrease in other long-term liabilities
-0 0 0
Accounts payable
-1,868 -564 -1,276 -509
Accrued expenses
-346 4,243 4,923 2,224
Operating right-of-use assets and operating lease liabilities, net
144 ---
Net cash used in operating activities
-25,571 -15,921 -15,550 -33,020
Purchases of property and equipment
6 7 --
Purchases of investments
10,726 90,022 17,841 55,228
Proceeds from sales and maturities of investments
33,187 32,884 37,479 91,094
Net cash provided by investing activities
22,455 -57,145 19,638 35,866
Proceeds from issuance of common stock and pre-funded warrants, net
-74,575 2,851 0
Repayment of short-term borrowings
-0 0 0
Repayment of long-term borrowings
-0 0 0
Net cash provided by (used in) financing activities
-74,575 2,851 0
Net (decrease) increase in cash, cash equivalents, and restricted cash
-3,116 1,509 6,939 2,846
Cash, cash equivalents, and restricted cash at beginning of the period
29,162 27,653 17,868 -
Cash, cash equivalents, and restricted cash at end of the period
26,046 29,162 27,653 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from sales andmaturities of investments$33,187K Net cash provided byinvesting activities$22,455K Canceled cashflow$10,732K Net (decrease)increase in cash, cash...-$3,116K Canceled cashflow$22,455K Stock-based compensationexpense$1,916K Other-$84K Depreciation expense$49K Purchases of investments$10,726K Purchases of property andequipment$6K Net cash used inoperating activities-$25,571K Canceled cashflow$2,049K Net loss-$22,969K Prepaid expenses andother current assets$1,947K Accounts payable-$1,868K Accrued expenses-$346K Net amortization ofpremiums and discounts on...$346K Operating right-of-useassets and operating...$144K

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals Holdings, Inc. (CRBP)